伴侣动物疼痛管理市场机会、成长动力、产业趋势分析及 2025 - 2034 年预测

2024年，全球伴侣动物疼痛管理市场规模达19亿美元，预计2034年将以6.2%的复合年增长率成长至34亿美元。宠物慢性病发病率的不断上升推动了这一稳定增长，也导致了对有效疼痛缓解解决方案的需求增加。此外，兽医治疗技术的进步和专用疼痛管理机构数量的不断增加也为市场扩张做出了重要贡献。随着兽医照护水准的提高，伴侣动物的寿命也随之延长，骨关节炎、术后不适和癌症相关疼痛等疾病也变得越来越普遍，对便利高效的疼痛管理工具的需求也随之增加。该行业涵盖了各种药品，例如非类固醇抗发炎药、鸦片类药物和麻醉药，以及旨在缓解犬、猫、马等动物急性和慢性疼痛的医疗器材。

2021年至2023年间，市场呈现持续的年增率，从2021年的16亿美元增至2022年的17亿美元，预计到2023年将达到18亿美元。这一上升趋势表明，宠物主人和兽医越来越意识到管理动物疼痛对于提高其生活品质的重要性。此外，包括缓释和调味口服药物在内的先进药物剂型的推出，使宠物主人和兽医专业人员能够更轻鬆地进行疼痛缓解，从而进一步提高了采用率。透皮贴片等创新给药系统的发展也在简化治疗方案和改善患者预后方面发挥了关键作用。

按动物类型划分，2024年，狗占据市场主导地位，创造了11亿美元的收入，预计到2034年将增长至19亿美元，复合年增长率为6.1%。这主要是由于狗的数量众多，且该群体中骨科疾病和慢性疾病的患病率较高，这极大地刺激了对疼痛缓解疗法的需求。

就产品类型而言，市场细分为药品和器械。药品领域在2024年引领全球市场，占据总市场份额的81.7%，预计在预测期内将以6%的复合年增长率成长。药物因其起效迅速且能有效治疗多种疼痛疾病，仍是兽医的第一线治疗手段。该领域包括非类固醇抗发炎药、鸦片类药物、麻醉药和其他药物类别。长效製剂和更易给药的药物等药物创新的不断进步，推动了兽医护理中对药物治疗的日益青睐。

根据应用，市场分为骨关节炎和关节痛、癌症、术后疼痛和其他用途。骨关节炎和关节痛细分市场在2024年的估值为8.072亿美元，预计在2025年至2034年期间的复合年增长率为6.4%。宠物（尤其是猫狗）中与年龄相关的关节疾病的增加是该细分市场扩张的关键因素。由于放射影像学、步态分析和活动追踪工具等诊断技术的进步，兽医专业人员现在能够更早诊断关节问题，从而导致治疗率激增，并推动了对疼痛管理解决方案的需求。

美国伴侣动物疼痛管理市场规模从2023年的7.542亿美元成长至2024年的7.957亿美元。预测期内，美国市场复合年增长率可望达到5.9%。这一增长背后有几个因素，包括宠物肌肉骨骼疾病的高发性、宠物饲养率的上升以及先进兽医护理基础设施的普及。越来越多的宠物主人将宠物的健康放在首位，这体现在越来越多地采用现代疼痛缓解方法，包括再生医学和替代疗法。涵盖各种疼痛治疗的保险计划的出现，进一步改善了人们获得医疗服务的机会。

全球前五大公司占据了约45%的市场。在竞争激烈的市场中，不乏一些知名企业，它们提供针对肌肉骨骼疼痛、髋关节发育不良和关节炎等疾病的先进止痛解决方案。这些公司凭藉着丰富的产品线、稳固的品牌影响力和广泛的分销管道，稳固了其市场地位。他们对研发的专注，以及日益增长的创新意识，正在持续塑造伴侣动物疼痛管理的未来。

目录

第一章：方法论与范围

第二章：执行摘要

第三章：行业洞察

• 产业生态系统分析
• 产业衝击力
  • 成长动力
    • 宠物拥有量的成长和宠物的人性化
    • 老年宠物患有关节炎和慢性疼痛的病例不断增加
    • 疼痛管理药物和设备的进步
    • 兽医保健支出增加
  • 产业陷阱与挑战
    • 兽医疼痛管理治疗费用高昂
    • 疼痛管理药物的严格监管审批
• 成长潜力分析
• 管道分析
• 未来趋势
• 监管格局
• 川普政府关税
  • 对贸易的影响
    • 贸易量中断
    • 报復措施
  • 对产业的影响
    • 供给侧影响（原料）
      • 主要材料价格波动
      • 供应链重组
      • 生产成本影响
    • 需求面影响（售价）
      • 价格传导至终端市场
      • 市占率动态
      • 消费者反应模式
  • 受影响的主要公司
  • 策略产业反应
    • 供应链重组
    • 定价和产品策略
    • 政策参与
  • 展望与未来考虑
• 波特的分析
• PESTEL分析

第四章：竞争格局

• 介绍
• 公司矩阵分析
• 主要市场参与者的竞争分析
• 竞争定位矩阵
• 策略仪表板

第五章：市场估计与预测：按动物类型，2021 - 2034 年

• 主要趋势
• 狗
• 猫
• 马匹
• 其他动物类型

第六章：市场估计与预测：依产品类型，2021 - 2034 年

• 主要趋势
• 药物
  • 类型
    • 非类固醇抗发炎药（NSAIDS）
    • 阿片类药物
    • 麻醉药
    • 其他药物类型
  • 给药途径
    • 口服
    • 肠外
    • 外用
  • 配销通路
    • 兽医院药房
    • 零售药局
    • 网路药局
• 装置
  • 雷射治疗
  • 电磁疗法

第七章：市场估计与预测：按应用，2021 - 2034 年

• 主要趋势
• 骨关节炎和关节痛
• 癌症
• 术后疼痛
• 其他应用

第八章：市场估计与预测：按地区，2021 - 2034 年

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 荷兰
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 澳洲
  • 韩国
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋

第九章：公司简介

• Aurora Pharmaceutical
• Bimeda
• Boehringer Ingelheim
• Ceva Sante Animale
• Chanelle Pharma
• Companion Animal Health
• Dechra Pharmaceuticals
• Elanco
• INDIBA
• Merck
• Norbrook
• PainTrace
• Vetaquinol
• Vetnation Pharma
• Virbac
• Zoetis

The global companion animal pain management market was valued at USD 1.9 billion in 2024 and is estimated to grow at a CAGR of 6.2% to reach USD 3.4 billion by 2034. This steady growth is fueled by the increasing incidence of chronic conditions in pets, which has led to a greater demand for effective pain relief solutions. Alongside this, technological progress in veterinary therapeutics and the rising number of dedicated pain management facilities are contributing significantly to market expansion. As companion animals live longer due to improved veterinary care, conditions such as osteoarthritis, post-surgical discomfort, and cancer-related pain are becoming more prevalent, creating a higher need for accessible and efficient pain management tools. The industry encompasses a wide range of pharmaceutical products such as NSAIDs, opioids, and anesthetics, as well as medical devices aimed at alleviating both acute and chronic pain in animals like dogs, cats, horses, and others.

Between 2021 and 2023, the market displayed consistent year-over-year growth, increasing from USD 1.6 billion in 2021 to USD 1.7 billion in 2022 and reaching USD 1.8 billion by 2023. This upward trend indicates an increasing awareness among pet owners and veterinarians about the importance of managing pain in animals to enhance their quality of life. Furthermore, the introduction of advanced drug formulations, including extended-release and flavored oral medications, has made it easier for both pet owners and veterinary professionals to administer pain relief, further boosting adoption rates. The development of innovative drug delivery systems, such as transdermal patches, has also played a critical role in simplifying treatment protocols and improving patient outcomes.

By animal type, dogs held the dominant market position in 2024, generating USD 1.1 billion in revenue and expected to grow to USD 1.9 billion by 2034 at a CAGR of 6.1%. This is largely due to the high dog population and the greater prevalence of orthopedic and chronic conditions in this group, which significantly contribute to the demand for pain relief therapies.

In terms of product type, the market is segmented into drugs and devices. The drugs segment led the global market in 2024, capturing 81.7% of the total share, and is anticipated to grow at a CAGR of 6% over the forecast period. Drugs remain the first-line treatment for veterinarians due to their rapid onset and effectiveness in managing a wide range of pain conditions. This segment includes NSAIDs, opioids, anesthetics, and other drug classes. The continuous enhancement in pharmaceutical innovation, such as long-acting formulations and easier-to-administer medications, supports the growing preference for drug-based treatments in veterinary care.

Based on application, the market is divided into osteoarthritis and joint pain, cancer, postoperative pain, and other uses. The osteoarthritis and joint pain segment garnered a valuation of USD 807.2 million in 2024 and is forecasted to grow at a CAGR of 6.4% between 2025 and 2034. The rise in age-related joint disorders among pets, particularly dogs and cats, is a key factor in this segment's expansion. Veterinary professionals are now able to diagnose joint problems earlier, thanks to advancements in diagnostic technologies such as radiography, gait analysis, and mobility tracking tools, leading to a surge in treatment rates and driving the demand for pain management solutions.

The companion animal pain management market in the United States was valued at USD 795.7 million in 2024, growing from USD 754.2 million in 2023. The country is poised to expand at a CAGR of 5.9% during the forecast period. Several factors underpin this growth, including the high occurrence of musculoskeletal issues in pets, the increasing rate of pet ownership, and access to advanced veterinary care infrastructure. More pet owners are prioritizing the well-being of their animals, which is reflected in the greater adoption of modern pain relief options, including regenerative medicine and alternative therapies. The availability of insurance plans that cover various pain treatments has further improved access to care.

Around 45% of the global market share is held by the top five companies. This competitive landscape includes several prominent players offering advanced pain relief solutions tailored for conditions like musculoskeletal pain, hip dysplasia, and arthritis. These companies maintain their market positions through extensive product offerings, well-established brand presence, and wide-reaching distribution channels. Their focus on research and development, coupled with a growing emphasis on innovation, continues to shape the future of pain management for companion animals.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Growing pet ownership and humanization of pets
    • 3.2.1.2 Rising cases of arthritis and chronic pain in aging pets
    • 3.2.1.3 Advances in pain management drugs and devices
    • 3.2.1.4 Increasing expenditure on veterinary healthcare
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High cost of veterinary pain management treatments
    • 3.2.2.2 Strict regulatory approvals for pain management drugs
• 3.3 Growth potential analysis
• 3.4 Pipeline analysis
• 3.5 Future trends
• 3.6 Regulatory landscape
• 3.7 Trump administration tariffs
  • 3.7.1 Impact on trade
    • 3.7.1.1 Trade volume disruptions
    • 3.7.1.2 Retaliatory measures
  • 3.7.2 Impact on the Industry
    • 3.7.2.1 Supply-side impact (raw materials)
      • 3.7.2.1.1 Price volatility in key materials
      • 3.7.2.1.2 Supply chain restructuring
      • 3.7.2.1.3 Production cost implications
    • 3.7.2.2 Demand-side impact (selling price)
      • 3.7.2.2.1 Price transmission to end markets
      • 3.7.2.2.2 Market share dynamics
      • 3.7.2.2.3 Consumer response patterns
  • 3.7.3 Key companies impacted
  • 3.7.4 Strategic industry responses
    • 3.7.4.1 Supply chain reconfiguration
    • 3.7.4.2 Pricing and product strategies
    • 3.7.4.3 Policy engagement
  • 3.7.5 Outlook and future considerations
• 3.8 Porter's analysis
• 3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Animal Type, 2021 - 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Dogs
• 5.3 Cats
• 5.4 Horses
• 5.5 Other animal types

Chapter 6 Market Estimates and Forecast, By Product Type, 2021 - 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Drugs
  • 6.2.1 Type
    • 6.2.1.1 Non-steroidal anti-inflammatory drugs (NSAIDS)
    • 6.2.1.2 Opioids
    • 6.2.1.3 Anesthetics
    • 6.2.1.4 Other drug types
  • 6.2.2 Route of administration
    • 6.2.2.1 Oral
    • 6.2.2.2 Parenteral
    • 6.2.2.3 Topical
  • 6.2.3 Distribution channel
    • 6.2.3.1 Veterinary hospitals pharmacies
    • 6.2.3.2 Retail pharmacies
    • 6.2.3.3 Online pharmacies
• 6.3 Devices
  • 6.3.1 Laser therapy
  • 6.3.2 Electromagnetic therapy

Chapter 7 Market Estimates and Forecast, By Application, 2021 - 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Osteoarthritis & joint pain
• 7.3 Cancer
• 7.4 Postoperative pain
• 7.5 Other applications

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE

Chapter 9 Company Profiles

• 9.1 Aurora Pharmaceutical
• 9.2 Bimeda
• 9.3 Boehringer Ingelheim
• 9.4 Ceva Sante Animale
• 9.5 Chanelle Pharma
• 9.6 Companion Animal Health
• 9.7 Dechra Pharmaceuticals
• 9.8 Elanco
• 9.9 INDIBA
• 9.10 Merck
• 9.11 Norbrook
• 9.12 PainTrace
• 9.13 Vetaquinol
• 9.14 Vetnation Pharma
• 9.15 Virbac
• 9.16 Zoetis